Gui‐Shuang Ying - Concepedia

Author

Gui‐Shuang Ying

Also Known As

G. Ying, G.-S. Ying, GUI-SHUANG YING, Gai Ying, Gang Ying, Gil Binenbaum, Gui Ying, Gui-Shuang Ying, Gui-shuang Ying, Guishuang Ying

725

Publications

23.2K

Citations

H-Index

171

Concepts

All Affiliations

University of Pennsylvania Penn Presbyterian Medical Center Children's Hospital of Philadelphia Cleveland Clinic Cleveland Eye Clinic

About

Gui‐Shuang Ying is an author at University of Pennsylvania specializing in medicine, ophthalmology, and age-related diseases.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	51	113	13K
2	Health Sciences	8	8	241
3	Education	7	9	985
4	Engineering	1	1	21
5	Nursing	1	1	106

Gui‐Shuang Ying

267

Publications

21.8K

Citations

H-Index

Page 1

	Year	Citations
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration Daniel Martín, Maureen G. Maguire, Stuart L. Fine, Ophthalmology Ocular DiseaseOphthalmologyAge-related DiseasesEye HealthGlaucoma	2012	1.7K
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial Albert M. Maguire, Katherine A. High, Alberto Auricchio, The Lancet Gene TherapiesGenetic DisorderGeneticsClinical TrialsTranslational Research	2009	849
Five-Year Outcomes with Anti–Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration Maureen G. Maguire, Daniel Martín, Gui‐Shuang Ying, Ophthalmology Five-year OutcomesOcular DiseaseCardiovascular DiseaseOphthalmologyAge-related Diseases	2016	683
Diabetic Retinopathy Preferred Practice Pattern® Christina J. Flaxel, Ron A. Adelman, Steven T. Bailey, Ophthalmology Diabetic RetinopathyOcular DiseaseOphthalmologyDiabetesMedicine	2019	659
Risk of Geographic Atrophy in the Comparison of Age-related Macular Degeneration Treatments Trials Juan E. Grunwald, Ebenezer Daniel, Jiayan Huang, Ophthalmology Ocular DiseaseOphthalmologyAge-related DiseasesGeographic AtrophyEye Health	2013	576
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration Francesca Simonelli, Albert M. Maguire, Francesco Testa, Molecular Therapy	2009	544
Genetic variants near <i>TIMP3</i> and high-density lipoprotein–associated loci influence susceptibility to age-related macular degeneration Wei Chen, Dwight Stambolian, Albert O. Edwards, Proceedings of the National Academy of Sciences	2010	511
AAV2 Gene Therapy Readministration in Three Adults with Congenital Blindness Jean Bennett, Manzar Ashtari, Jennifer Wellman, Science Translational Medicine Gene TherapiesTranslational MedicineRpe65 GeneRetinaIn Vivo Gene Therapy	2012	387
Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis Lauren Talman, Esther R. Bisker, David J. Sackel, Annals of Neurology	2010	362
Age-Related Macular Degeneration Preferred Practice Pattern® Christina J. Flaxel, Ron A. Adelman, Steven T. Bailey, Ophthalmology MedicineAge-related DiseasesOcular DiseaseOphthalmology	2019	324

Page 1